Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation.
Level 4 - case-series / case-control
Uncontrolled prospective cohort / case series comparing outcomes across ApoE genotypes
PubMed 27677546 · doi:10.1096/fj.201600677RR
What was done
Patients initially diagnosed with mild cognitive impairment (MCI) or subjective cognitive impairment (SCI) self-supplemented with a daily drink containing omega-3 fatty acids, antioxidants, and resveratrol. Researchers tracked changes in Mini-Mental State Examination (MMSE) scores, macrophage phenotype (ratio of inflammatory CD54+CD80 to pro-resolution CD163+CD206 markers), and macrophage amyloid-β 1-42 (Aβ 1-42) phagocytosis over time, stratified by apolipoprotein E genotype (ApoE ε3/ε3 vs. ApoE ε3/ε4). In vitro effects of resolvin D1 (RvD1) on macrophage polarization were also evaluated.
What was found
At baseline, median MMSE was 26.0 in both ApoE groups, and macrophage Aβ 1-42 phagocytosis was defective. During supplementation, the annualized MMSE rate of change increased by a median of 2.2 points per year in the ApoE ε3/ε3 group (P = 0.015), with all patients remaining stable or improving. In the ApoE ε3/ε4 group, MMSE did not change significantly (P = 0.014 between groups); 1 patient recovered from dementia while 3 progressed to dementia. Macrophage phenotype shifted toward an intermediate M1-M2 profile at a rate of 0.226 U/year in ApoE ε3/ε3 carriers, but polarization was negative in ε3/ε4 carriers (P = 0.08 between groups). Aβ 1-42 phagocytosis increased significantly in both groups (P = 0.03 in each). In vitro, RvD1 downregulated M1 markers in ε3/ε3 macrophages but paradoxically upregulated M1 markers in some ε3/ε4 samples.
Why it matters
This study suggests that cognitive and immune responses to multi-nutrient supplementation with omega-3s and antioxidants may differ markedly depending on ApoE genotype, pointing toward potential genotype-specific mechanisms in macrophage amyloid clearance.
Limits
The study was open-label and uncontrolled, precluding causal attribution. Total sample size is not stated in the abstract, the intervention was self-administered as a multi-ingredient mixture making specific active components unidentifiable, and the authors explicitly note the study is limited by small size.
Cited by
- context Patients with Alzheimer's disease show a reduced capacity of peripheral blood mononuclear cells/macrophages to phagocytose beta-amyloid, which returns to normal following the Bredesen protocol.